AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29131740 — intervention group
Group type: COMPARATOR
Intervention: Attention control educational group
Number of subjects: 52
Study 25744158 — intervention group
Group type: COMPARATOR
Intervention: Erythritol 20 g
Number of subjects: 185
Study 25744158 — intervention group
Group type: COMPARATOR
Intervention: Erythritol 25 g
Number of subjects: 185
Study 25744158 — intervention group
Group type: COMPARATOR
Intervention: Erythritol 15 g
Number of subjects: 185
Study 25744158 — intervention group
Group type: COMPARATOR
Intervention: Erythritol 5 g
Number of subjects: 185
Study 25744158 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (isosweet sucrose)
Number of subjects: 185
Study 23535137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8
Study 23535137 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 8
Study 23535137 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 8
Study 23535137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 21370769 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional manual therapy techniques to the temporomandibular region
Number of subjects: 43
Study 21370769 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (manual therapy for the cervical region)
Number of subjects: 43
Study 19227169 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (ropivacaine 0.18% and fentanyl 45.5 microg x ml(‐1) at 2 ml x hr(‐1))
Number of subjects: 32
Study 19227169 — intervention group
Group type: COMPARATOR
Intervention: Continuous hypodermic infusion (morphine 0.04 mg x kg(‐1) x ml(‐1) at 0.5 ml x hr(‐1); bolus: 0.5 ml x hr(‐1))
Number of subjects: 32
Study 16877271 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 12
Study 16877271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12942279 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Buscopan
Number of subjects: 73
Study 12942279 — intervention group
Group type: COMPARATOR
Intervention: No muscle relaxant
Number of subjects: 73
Study 10868317 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg bid)
Number of subjects: 24
Study 10868317 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin and Celecoxib
Number of subjects: 24
Study 10868317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8938878 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Diclofenac eye-drops
Number of subjects: 25
Study 8938878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1590949 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere lesions
Number of subjects: 70
Study 1590949 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere lesions
Number of subjects: 70
Study 1590949 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 70
Study 3987303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical prosthetic valve (Björk‐Shiley)
Number of subjects: 0
Study 3987303 — intervention group
Group type: COMPARATOR
Intervention: Bioprosthesis (Hancock porcine heterograft valve)
Number of subjects: 0
Study 31283765 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian change-point detection model
Number of subjects: 0
Study 31283765 — intervention group
Group type: COMPARATOR
Intervention: Alternative models (approximate Bayesian to simple heuristics)
Number of subjects: 0
Study 29222135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory treatment (OP)
Number of subjects: 152
Study 29222135 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment (IP)
Number of subjects: 152
Study 25722532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued patients with MS (n = 21)
Number of subjects: 35
Study 25722532 — intervention group
Group type: COMPARATOR
Intervention: Non-fatigued patients with MS (n = 14)
Number of subjects: 35
Study 25722532 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 (pro-inflammatory cytokine)
Number of subjects: 35
Study 24694475 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids alone (methylprednisolone, MP group; n=25)
Number of subjects: 48
Study 24694475 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids plus cyclosporine A (combination group; n=23)
Number of subjects: 48
Study 21600712 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone plates (Group S)
Number of subjects: 35
Study 21600712 — intervention group
Group type: COMPARATOR
Intervention: Gauze packing (Group G)
Number of subjects: 35
Study 20128667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice application to the ankle joint
Number of subjects: 24
Study 17557322 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior tibial post contact
Number of subjects: 11
Study 17557322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperextension angles
Number of subjects: 11
Study 17557322 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral component flexion
Number of subjects: 11
Study 16353397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus self-rating scale for loudness (six-point response scale)
Number of subjects: 273
Study 16353397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus self-rating scale for annoyance (eight-point response scale)
Number of subjects: 273
Study 16353397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus self-rating scale for change (six-point response scale)
Number of subjects: 273
Study 12014100 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 154
Study 12014100 — intervention group
Group type: COMPARATOR
Intervention: Lack of physical activity
Number of subjects: 154
Study 12014100 — intervention group
Group type: COMPARATOR
Intervention: Obesity
Number of subjects: 154
Study 10594412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 75
Study 10594412 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 75
Study 8786250 — intervention group
Group type: EXPERIMENTAL
Intervention: PABA 1.5 g orally every 6 hours for 5 days with intravenous procainamide 750 mg
Number of subjects: 11
Study 8786250 — intervention group
Group type: COMPARATOR
Intervention: Intravenous procainamide alone
Number of subjects: 11
Study 2190664 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary excision and grafting
Number of subjects: 25
Study 2190664 — intervention group
Group type: COMPARATOR
Intervention: Defatting the flap
Number of subjects: 25
Study 37493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2 x 1 mg)
Number of subjects: 27
Study 37493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2 x 2 mg)
Number of subjects: 27
Study 37493 — intervention group
Group type: COMPARATOR
Intervention: Clemastine (2 x 1 mg)
Number of subjects: 27
Study 37493 — intervention group
Group type: COMPARATOR
Intervention: Cromoglycate (Intal)
Number of subjects: 27
Study 37493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (3 and 14 days after treatment)
Number of subjects: 27
Study 31449576 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA + CM
Number of subjects: 0
Study 31449576 — intervention group
Group type: COMPARATOR
Intervention: DFDBA
Number of subjects: 0
Study 28921654 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration (0.0 and 0.65 g/kg)
Number of subjects: 50
Study 28921654 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study 25931212 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 Hz low frequency rTMS (n=21)
Number of subjects: 60
Study 25931212 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz high frequency rTMS (n=21)
Number of subjects: 60
Study 25931212 — intervention group
Group type: COMPARATOR
Intervention: False stimulation (control group, n=18)
Number of subjects: 60
Study 23675620 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine EMFs exposure (GSM cellular phone at 900 MHz, 2 W)
Number of subjects: 26
Study 23675620 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 26
Study 21852542 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg
Number of subjects: 106
Study 21852542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 19028832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic methylprednisolone (MP) in combination with azathioprine (AZA) for 6 months
Number of subjects: 27
Study 19028832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study 18021866 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 0
Study 16338193 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-disc
Number of subjects: 80
Study 16338193 — intervention group
Group type: COMPARATOR
Intervention: Placebo disc
Number of subjects: 80
Study 12022001 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens correction for myopias > 11 D
Number of subjects: 88
Study 12022001 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens correction for hyperopias > 9 D
Number of subjects: 88
Study 12022001 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens correction for myopias > 18 D
Number of subjects: 88
Study 12022001 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens correction for hyperopias > 13 D
Number of subjects: 88
Study 12022001 — intervention group
Group type: COMPARATOR
Intervention: No contact lens correction
Number of subjects: 88
Study 10382340 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of the patient, reducing fear, avoiding bedrest and inactivity
Number of subjects: 0
Study 10382340 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 7872215 — intervention group
Group type: COMPARATOR
Intervention: Standard preterm formula (without long-chain polyunsaturated fatty acids)
Number of subjects: 35
Study 7872215 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula (with long-chain polyunsaturated fatty acids)
Number of subjects: 35
Study 7872215 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk fortified with protein and energy
Number of subjects: 35
Study 2397973 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine cream 1%
Number of subjects: 70
Study 2397973 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 70
Study 373103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1.6 g/day)
Number of subjects: 36
Study 373103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31405646 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (100 μg or 4000 IU daily)
Number of subjects: 68
Study 31405646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30241993 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT
Number of subjects: 131
Study 30241993 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered child-directed play (active control)
Number of subjects: 131
Study 30241993 — intervention group
Group type: COMPARATOR
Intervention: ICBT vs Control
Number of subjects: 131
Study 27327921 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-gravity gait training using the AlterG® Anti-Gravity Treadmill®
Number of subjects: 30
Study 27327921 — intervention group
Group type: COMPARATOR
Intervention: Land-based gait training
Number of subjects: 30
Study 24355401 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus TMC plus incentives for session attendance (TMC+)
Number of subjects: 321
Study 24355401 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus Telephone Monitoring and Counseling (TMC)
Number of subjects: 321
Study 24355401 — intervention group
Group type: COMPARATOR
Intervention: IOP treatment as usual (TAU)
Number of subjects: 321
Study 22933802 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography in young individuals
Number of subjects: 20
Study 22933802 — intervention group
Group type: COMPARATOR
Intervention: Magnetoencephalography in middle-aged individuals
Number of subjects: 20
Study 22933802 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical regression analysis
Number of subjects: 20
Study 22933802 — intervention group
Group type: EXPERIMENTAL
Intervention: FA of the uncinate fasciculus
Number of subjects: 20
Study 22933802 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related reductions in left-lateralization of language responses
Number of subjects: 20
Study 22933802 — intervention group
Group type: EXPERIMENTAL
Intervention: N400 reductions
Number of subjects: 20
Study 20100765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition labeling on menus
Number of subjects: 99
Study 20100765 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutrition labeling)
Number of subjects: 99
Study 17631219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 75
Study 17631219 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 75
Study 16157401 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous accelerated postoperative irradiation (p-CAIR) - 63 Gy in 1.8 Gy fractions 7-days-a-week over 5 weeks
Number of subjects: 175
Study 16157401 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated postoperative radiotherapy (p-CF) - 63 Gy in 1.8 Gy fractions 5-days-a-week over 7 weeks
Number of subjects: 175
Study 12916135 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom
Number of subjects: 1442
Study 12916135 — intervention group
Group type: COMPARATOR
Intervention: Male condom
Number of subjects: 1442
Study 12916135 — intervention group
Group type: COMPARATOR
Intervention: Comparison of STD occurrence
Number of subjects: 1442
Study 12916135 — intervention group
Group type: COMPARATOR
Intervention: Comparison of incidence rates
Number of subjects: 1442
Study 10503688 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal penicillin prophylaxis (PP)
Number of subjects: 10998
Study 7537170 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole-D (10 mg astemizole plus 240 mg pseudoephedrine) once daily
Number of subjects: 204
Study 7537170 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone nasal spray (0.05 mg/ml) two puffs/nostril twice daily
Number of subjects: 204
Study 2109515 — intervention group
Group type: EXPERIMENTAL
Intervention: Norinyl 1/35
Number of subjects: 150
Study 2109515 — intervention group
Group type: EXPERIMENTAL
Intervention: Lo-Ovral
Number of subjects: 150
Study 2109515 — intervention group
Group type: EXPERIMENTAL
Intervention: Noriday 1/50
Number of subjects: 150
Study 399592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrallazine
Number of subjects: 5
Study 399592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 5
Study 399592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol plus Hydrallazine
Number of subjects: 5
Study 399592 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol alone
Number of subjects: 5
Study 399592 — intervention group
Group type: COMPARATOR
Intervention: Hydrallazine alone
Number of subjects: 5
Study 31913907 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) for stage I NSCLC
Number of subjects: 174
Study 31307651 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial plexus group
Number of subjects: 163
Study 31307651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbosacral plexus group
Number of subjects: 163
Study 31307651 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging group
Number of subjects: 163
Study 31307651 — intervention group
Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 163
Study 27615161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 412
Study 27615161 — intervention group
Group type: COMPARATOR
Intervention: Active control (sevelamer carbonate and/or calcium acetate)
Number of subjects: 412
Study 25538152 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise (19 weeks, 3 times/week)
Number of subjects: 40
Study 25538152 — intervention group
Group type: COMPARATOR
Intervention: Stretching (control group)
Number of subjects: 40
Study 23649216 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 100
Study 23649216 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study 20615905 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced eGFR in participants aged 18-29 years (2.6%)
Number of subjects: 771
Study 20615905 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced eGFR in participants aged 30-41 years (7.4%)
Number of subjects: 771
Study 20615905 — intervention group
Group type: COMPARATOR
Intervention: Dipstick proteinuria of 1+ or greater in cases (27%)
Number of subjects: 771
Study 20615905 — intervention group
Group type: COMPARATOR
Intervention: Haematuria in cases (24%)
Number of subjects: 771
Study 20615905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension and residence at lower altitude
Number of subjects: 771
Study 20615905 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational history
Number of subjects: 771
Study 19761652 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg Zn2+/day)
Number of subjects: 26
Study 19761652 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 26
Study 16720138 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefazolin (group A)
Number of subjects: 277
Study 16720138 — intervention group
Group type: COMPARATOR
Intervention: 10 mL isotonic sodium chloride solution (group B; control)
Number of subjects: 277
Study 15381645 — intervention group
Group type: EXPERIMENTAL
Intervention: US patients (intervention group)
Number of subjects: 26003
Study 15381645 — intervention group
Group type: COMPARATOR
Intervention: Canadian patients (control group)
Number of subjects: 26003
Study 15381645 — intervention group
Group type: EXPERIMENTAL
Intervention: Country (US vs Canada)
Number of subjects: 26003
Study 11760033 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone phosphate eye gel
Number of subjects: 236
Study 11760033 — intervention group
Group type: COMPARATOR
Intervention: 1% prednisolone acetate eye suspension
Number of subjects: 236
Study 9159563 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide administered as a slow-rate infusion
Number of subjects: 7
Study 9159563 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide administered in combination with 2 g of probenecid
Number of subjects: 7
Study 9159563 — intervention group
Group type: COMPARATOR
Intervention: Frusemide bolus dose
Number of subjects: 7
Study 8518372 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 36
Study 8518372 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 36
Study 3683453 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of mixed gangliosides (Cronassial)
Number of subjects: 37
Study 3683453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31838596 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic milk (Lactobacillus paracasei SD1) daily (group II)
Number of subjects: 487
Study 31838596 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic milk (Lactobacillus paracasei SD1) triweekly (group III)
Number of subjects: 487
Study 31838596 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk (group I)
Number of subjects: 487
Study 31033133 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat extract oil (WEO)
Number of subjects: 64
Study 31033133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 28034704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidants (2 g ascorbate, 1.2 g N-acetylcysteine, 600 mg lipoic acid, 30 mg beta carotene)
Number of subjects: 10
Study 28034704 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidants)
Number of subjects: 10
Study 25421868 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosing of naftopidil
Number of subjects: 143
Study 25421868 — intervention group
Group type: COMPARATOR
Intervention: Morning dosing of naftopidil
Number of subjects: 143
Study 24024769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium nicotinate 50 μg (NC50)
Number of subjects: 56
Study 24024769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium nicotinate 200 μg (NC200)
Number of subjects: 56
Study 24024769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NC0)
Number of subjects: 56
Study 21454723 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 4351
Study 21454723 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 4351
Study 21454723 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 4351
Study 18321515 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment before infertility treatment
Number of subjects: 140
Study 16490000 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 21
Study 16490000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 14751919 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatments for prostate cancer
Number of subjects: 129
Study 11397883 — intervention group
Group type: EXPERIMENTAL
Intervention: Estring treatment (7.5 microg per 24 h)
Number of subjects: 70
Study 11397883 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 70
Study 9268185 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma response to activated protein C (APC)
Number of subjects: 4000
Study 9268185 — intervention group
Group type: EXPERIMENTAL
Intervention: APC-ratio
Number of subjects: 4000
Study 8503751 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, intensive, gait‐focused physical therapy
Number of subjects: 27
Study 8503751 — intervention group
Group type: COMPARATOR
Intervention: Early, intensive and conventional therapy
Number of subjects: 27
Study 8503751 — intervention group
Group type: COMPARATOR
Intervention: Routine conventional therapy that started later and was not intense
Number of subjects: 27
Study 3103901 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate
Number of subjects: 48